Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges
Enrique Sanz‐García, Eric Y. Stutheit-Zhao, Scott V. Bratman, et al.
Science Advances (2022) Vol. 8, Iss. 4
Open Access | Times Cited: 103

Showing 1-25 of 103 citing articles:

Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
Miguel García-Pardo, Maisam Makarem, Janice J.N. Li, et al.
British Journal of Cancer (2022) Vol. 127, Iss. 4, pp. 592-602
Open Access | Times Cited: 72
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
Zoe J. Assaf, Wei Zou, Alexander D. Fine, et al.
Nature Medicine (2023) Vol. 29, Iss. 4, pp. 859-868
Open Access | Times Cited: 64
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Jordi Remón, Benjamin Besse, Santiago Ponce Aix, et al.
Annals of Oncology (2023) Vol. 34, Iss. 5, pp. 468-476
Closed Access | Times Cited: 37
Emerging digital PCR technology in precision medicine
Lexiang Zhang, Rokshana Parvin, Qihui Fan, et al.
Biosensors and Bioelectronics (2022) Vol. 211, pp. 114344-114344
Closed Access | Times Cited: 60
Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation
Haonan Li, Qiang Luo, Hu Zhang, et al.
Chemical Society Reviews (2022) Vol. 52, Iss. 1, pp. 47-96
Closed Access | Times Cited: 37
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
Mohamed A. Gouda, Filip Janků, Adam Wahida, et al.
Annals of Oncology (2023) Vol. 35, Iss. 3, pp. 267-275
Open Access | Times Cited: 29
The functional and clinical roles of liquid biopsy in patient-derived models
Ziqing Zhu, Erya Hu, Hong Shen, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 24
Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches
Farah Raheem, Suganya Arunachalam Karikalan, Felipe Batalini, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16198-16198
Open Access | Times Cited: 24
CRISPR-Cas12a Biosensor Array for Ultrasensitive Detection of Unamplified DNA with Single-Nucleotide Polymorphic Discrimination
Zhengyan Weng, Zheng You, Huijie Li, et al.
ACS Sensors (2023) Vol. 8, Iss. 4, pp. 1489-1499
Closed Access | Times Cited: 22
Liquid biopsy: Cell-free DNA based analysis in breast cancer
Konstantinos Venetis, Giulia Cursano, Carlo Pescia, et al.
The Journal of Liquid Biopsy (2023) Vol. 1, pp. 100002-100002
Open Access | Times Cited: 20
An Ion Concentration Polarization Microplatform for Efficient Enrichment and Analysis of ctDNA
Zhiying Wang, Ming Liu, Haocheng Lin, et al.
ACS Nano (2024) Vol. 18, Iss. 4, pp. 2872-2884
Closed Access | Times Cited: 11
Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy
Suling Xu, Qing-Qing Wang, Wenxue Ma
Cytokine & Growth Factor Reviews (2024) Vol. 76, pp. 12-21
Closed Access | Times Cited: 9
High‐Viability Circulating Tumor Cells Sorting From Whole Blood at Single Cell Level Using Laser‐Induced Forward Transfer‐Assisted Microfiltration
Qingmei Xu, Yuntong Wang, Songtao Dou, et al.
Advanced Science (2025)
Open Access
S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer
Hongnan Mo, Xuefeng Liu, Yu Xue, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 29
The Future of Precision Oncology
Stuart L. Rulten, Richard Grose, Susanne A. Gatz, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12613-12613
Open Access | Times Cited: 18
Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review
Laith Al-Showbaki, Brooke E. Wilson, Faris Tamimi, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 2, pp. e005854-e005854
Open Access | Times Cited: 15
Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer
Hideki Motobayashi, Yuji Kitahata, Ken‐ichi Okada, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 2
Open Access | Times Cited: 4
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Eric Y. Stutheit-Zhao, Enrique Sanz‐García, Zhihui Amy Liu, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 1048-1063
Open Access | Times Cited: 4
Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay
Josette Northcott, Gábor Bartha, Jason Harris, et al.
Oncotarget (2024) Vol. 15, Iss. 1, pp. 200-218
Open Access | Times Cited: 4
The Role of Cell-Free DNA in Cancer Treatment Decision Making
András Telekes, Anna Horváth
Cancers (2022) Vol. 14, Iss. 24, pp. 6115-6115
Open Access | Times Cited: 21
Clonal Evolution in Healthy and Premalignant Tissues: Implications for Early Cancer Interception Strategies
Jayant K. Rane, Alexander M. Frankell, Clare E. Weeden, et al.
Cancer Prevention Research (2023) Vol. 16, Iss. 7, pp. 369-378
Open Access | Times Cited: 11
Redefining precision radiotherapy through liquid biopsy
Duncan B. McLaren, Timothy J. Aitman
British Journal of Cancer (2023) Vol. 129, Iss. 6, pp. 900-903
Open Access | Times Cited: 11
Sensitive circulating tumor DNA–based residual disease detection in epithelial ovarian cancer
Heini Kallio, Kalle Savolainen, Tuomo Virtanen, et al.
Life Science Alliance (2024) Vol. 7, Iss. 6, pp. e202402658-e202402658
Open Access | Times Cited: 4
A Practical Approach to Interpreting Circulating Tumor DNA in the Management of Gastrointestinal Cancers
Zexi Allan, David S. Liu, Margaret M Lee, et al.
Clinical Chemistry (2024) Vol. 70, Iss. 1, pp. 49-59
Closed Access | Times Cited: 3
Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib
Anyue Yin, G. Veerman, J. G. Coen van Hasselt, et al.
CPT Pharmacometrics & Systems Pharmacology (2024) Vol. 13, Iss. 4, pp. 612-623
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top